Bedaquiline tablets 100mg/tablet, 188 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• In clinical trials of patients with tuberculosis treated with LuciBeda, there was an imbalance in mortality due to Mycobacterium tuberculosis resistance to at least rifampicin.
• Hepatotoxicity may occur with LuciBeda. Please monitor the results of liver-related laboratory tests. In case of evidence of liver damage, discontinue LuciBeda.

Medication risks

Adverse Reactions
• In Study 1, nausea, joint pain, headache, hemoptysis, and chest pain were the most common adverse reactions reported in 10% or more of the adult patients treated with LuciBeda.
• In Study 4, the most common adverse reactions reported in 10% or more of adult patients treated with LuciBeda (40-week group) were prolonged QTc interval, nausea, vomiting, joint pain, elevated transaminases, abdominal pain, itching, dizziness, headache, chest pain, rash, insomnia, dry skin, and palpitation.
• Arthralgia, nausea, and abdominal pain were the most common adverse reactions reported in 10% or more of pediatric patients (12 to 18 years of age) treated with LuciBeda.
• The most common adverse reaction reported in 10% or more of pediatric patients (ages 5 to 12) treated with LuciBeda was increased hepatic enzymes.